Literature DB >> 35311710

You've Got a Friend in Me: How Cognitively Unimpaired Older Adults Select a Study Partner to Participate with Them in Alzheimer's Disease Research.

Emily A Largent1, Twisha Bhardwaj2, Justin T Clapp3, Olivia Saúl Sykes4, Kristin Harkins4, Joshua D Grill5.   

Abstract

BACKGROUND: Participants in Alzheimer's disease (AD) prevention studies are generally required to enroll with a study partner; this requirement constitutes a barrier to enrollment for some otherwise interested individuals. Analysis of dyads enrolled in actual AD trials suggests that the study partner requirement shapes the population under study.
OBJECTIVE: To understand if individuals can identify someone to serve as their study partner and whether they would be willing to ask that individual.
METHODS: We conducted semi-structured interviews with cognitively unimpaired, English-speaking older adults who had previously expressed interest in AD research by signing up for a research registry. We also interviewed their likely study partners. Audio-recorded interviews were transcribed and coded in an iterative, team-based process guided by a content analysis approach.
RESULTS: We interviewed 60 potential research participants and 17 likely study partners. Most potential participants identified one or two individuals they would be willing to ask to serve as their study partner. Interviewees saw value in the study partner role but also understood it to entail burdens that could make participation as a study partner more difficult. The role was seen as relatively more burdensome for individuals in the workforce or with family responsibilities. Calls from the researcher to discuss the importance of the role and the possibility of virtual visits were identified as potential strategies for increasing study partner availability.
CONCLUSION: Efforts to increase recruitment, particularly representative recruitment, of participants for AD prevention studies should reduce barriers to participation by thoughtfully designing the study partner role.

Entities:  

Keywords:  Alzheimer’s disease; ethics; registries; research; research design

Year:  2022        PMID: 35311710      PMCID: PMC9482665          DOI: 10.3233/JAD-220061

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.160


  36 in total

1.  How do AD patients and their caregivers decide whether to enroll in a clinical trial?

Authors:  J H Karlawish; D Casarett; J Klocinski; P Sankar
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

2.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

Review 3.  Neuropsychological Test Administration by Videoconference: A Systematic Review and Meta-Analysis.

Authors:  Timothy W Brearly; Robert D Shura; Sarah L Martindale; Rory A Lazowski; David D Luxton; Brian V Shenal; Jared A Rowland
Journal:  Neuropsychol Rev       Date:  2017-06-16       Impact factor: 7.444

4.  The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions.

Authors:  Keith N Fargo; Maria C Carrillo; Michael W Weiner; William Z Potter; Zaven Khachaturian
Journal:  Alzheimers Dement       Date:  2016-11       Impact factor: 21.566

5.  Obstacles and opportunities in Alzheimer's clinical trial recruitment.

Authors:  Jennifer L Watson; Laurie Ryan; Nina Silverberg; Vicky Cahan; Marie A Bernard
Journal:  Health Aff (Millwood)       Date:  2014-04       Impact factor: 6.301

6.  A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners.

Authors:  Chelsea G Cox; Mary M Ryan B A; Daniel L Gillen; Joshua D Grill
Journal:  Am J Geriatr Psychiatry       Date:  2018-11-03       Impact factor: 4.105

7.  The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment.

Authors:  Shana D Stites; Jeanine Gill; Emily A Largent; Kristin Harkins; Pamela Sankar; Abba Krieger; Jason Karlawish
Journal:  Soc Sci Med       Date:  2021-12-01       Impact factor: 4.634

8.  Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.

Authors:  P Aisen; J Touchon; S Andrieu; M Boada; R Doody; R L Nosheny; J B Langbaum; L Schneider; S Hendrix; G Wilcock; J L Molinuevo; C Ritchie; P-J Ousset; J Cummings; R Sperling; S T DeKosky; S Lovestone; H Hampel; R Petersen; V Legrand; M Egan; C Randolph; S Salloway; M Weiner; B Vellas
Journal:  J Prev Alzheimers Dis       Date:  2016

9.  Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Authors:  Ryan D Nipp; Hang Lee; Elizabeth Powell; Nicole E Birrer; Emily Poles; Daniel Finkelstein; Karen Winkfield; Sanja Percac-Lima; Bruce Chabner; Beverly Moy
Journal:  Oncologist       Date:  2016-03-14

10.  Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer's trials.

Authors:  Michelle M Nuño; Daniel L Gillen; Joshua D Grill
Journal:  Alzheimers Res Ther       Date:  2019-11-27       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.